HemCon Medical Technologies, Inc. Announces New Research on ChitoGauze® Published in Leading European Trauma Journal - KMPH FOX 26 | Central San Joaquin Valley News Source

HemCon Medical Technologies, Inc. Announces New Research on ChitoGauze® Published in Leading European Trauma Journal

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE TriStar Wellness Solutions

Use of HemCon's Hemostatic Technology for Massive Bleeding Control in Dutch Life Flight Helicopters

WESTPORT, Conn., June 12, 2014 /PRNewswire/ -- HemCon Medical Technologies, Inc. ("HemCon"), a wholly owned subsidiary of TriStar Wellness Solutions(R), Inc. (OTCQB: TWSI) and a leading developer and marketer of advanced medical products, announced today that Authors Dr. E.C.T.H. Tan and Dr. J. Peters have published in the Dutch Journal of TraumaSurgery encouraging results of a study conducted between 2009 and 2013 using HemCon's hemostatic chitosan-coated dressing ChitoGauze® on pre-hospital bleeding patients by one of the four Dutch Helicopter-Mobile Medical Teams; the Lifeliner3 of the Radboud University Medical Center, Nijmegen the Netherlands.

Photo - http://photos.prnewswire.com/prnh/20140611/117207
Photo - http://photos.prnewswire.com/prnh/20140611/117184

During the study all injured trauma patients with massive bleeding were successfully treated with HemCon ChitoGauze. Seventy five percent (75%) of all bleeding could be stopped with application of ChitoGauze, while in twenty five percent (25%) of patients ChitoGauze helped to control the severity of bleeding. No side effects were noted in the available follow up of 85.7% of all study subjects. The conclusion of this study is that all degrees (arterial, venous or combination of arterial and venous) of bleeding could be stopped with the HemCon dressing and this offers emergency medical personnel in both civilian and military settings a versatile and highly effective hemostatic solution to help safely stabilize patient for transport to definitive care.

"ChitoGauze has a proven track record of quickly controlling all types of bleeding. HemCon's proprietary chitosan technology provides a cost-effective hemostatic solution to treat routine to most compromised patients, while also providing antibacterial properties that may help reduce the risk of infection. HemCon's ability to stop bleeding at all levels of the continuum of care allows hospitals to add efficiencies to their normal practices as well as greatly reducing everyday expenses, while improving patient outcomes," said Michael Wax, President and CEO, HemCon. "We are very gratified that this important research conducted by Dr. Tan and Dr. Peters has been published and is being presented to the trauma community."

Dr. Tan recently presented the study at the Scientific Program of the European Congress of 
Trauma and Emergency Surgery (ECTES)/World Trauma Congress in Frankfurt, Germany. Results will also be presented by Dr. Peters at the AIRMED World Congress in Rome, Italy in June. "This international exposure solidifies the recent decision of the U.S. Military Committee on Combat Casualty Care (CoTCCC) to add ChitoGauze to their guidelines for hemorrhage control in tactical field and evacuation care." Added Mr. Wax.

For Instant Alerts and future press releases Text: TWSI to 40691 "standard text mssg and data rates may apply

About HemCon Medical Technologies

HemCon Medical Technologies Inc., founded in 2001, develops, manufactures, and markets innovative technologies for hemostatic devices for the control of bleeding resulting from trauma or surgery. HemCon products are designed for use by military and civilian first responders as well as medical professionals in hospital and clinical settings where control of bleeding are of critical importance. HemCon is headquartered in Portland, Ore. With a 36,000 sq. ft. state of the art manufacturing facility, the Company has additional commercial operations in Ireland and the Czech Republic. For more information, please visit www.hemcon.com.

About TriStar Wellness Solutions

TriStar Wellness Solutions®, Inc. (TWSI) is a health and wellness company that targets under-met consumer opportunities in the OTC and professional marketplace. Its core strategy plans to meet the growing demand for personalized, care solutions by leveraging proprietary innovation and healthcare technology with the rapid transformation of the healthcare marketplace to create innovative, science based solutions and brands. TriStar recently acquired HemCon Medical Technologies Inc., a developer, manufacturer, and marketer of innovative technologies for hemostatic devices for the control of bleeding resulting from trauma or surgery. It also owns the Beauty de MamanTM brand of women's health products. Additional information is available at www.tstarwellness.com.

Forward-Looking Statement

This press release for TriStar Wellness Solutions®, Inc. contains forward-looking statements. Generally, you can identify these statements because they use words like "anticipates," "believes," "expects," "future," "intends," "plans," and similar terms. These statements reflect only our current expectations. Although we do not make forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy and actual results may differ materially from those we anticipated due to a number of uncertainties, many of which are unforeseen, including, among others, the risks we face as described our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements which apply only as of the date of this press release. To the extent that such statements are not recitations of historical fact, such statements constitute forward-looking statements that, by definition, involve risks and uncertainties. In any forward-looking statement where we express an expectation or belief as to future results or events, such expectation or belief is expressed in good faith and believed to have a reasonable basis, but there can be no assurance that the statement of expectation of belief will be accomplished.

Contact: 
Simona Buergi 
Tel: (503) 245-0459 
simona.buergi@hemcon.com

Web site: http://www.tstarwellness.com  

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow
All content © Copyright 2000 - 2014 WorldNow and KMPH. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.